Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     
  • OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD

    2,406.70
    +8.70 (+0.36%)
     
  • Bitcoin AUD

    99,253.88
    +5,479.66 (+5.84%)
     
  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     
  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     
  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Medtronic Earnings, Revenue Beat in Q2

Medtronic Earnings, Revenue Beat in Q2
Medtronic Earnings, Revenue Beat in Q2

Investing.com - Medtronic reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.

The firm reported earnings per share of $1.31 on revenue of $7.71B. Analysts polled by Investing.com forecast EPS of $1.28 on revenue of $7.66B. That compared to EPS of $1.22 on revenue of $7.5B in the same period a year earlier. The company had reported EPS of $1.26 on revenue of $7.49B in the previous quarter.

Medtronic follows other major Healthcare sector earnings this month

On October 29, Merck&Co reported third quarter EPS of $1.51 on revenue of $12.4B, compared to forecasts of EPS of $1.24 on revenue of $11.64B.

ADVERTISEMENT

Novartis ADR earnings beat analysts' expectations on October 22, with third quarter EPS of $1.41 on revenue of $12.17B. Investing.com analysts expected EPS of $1.32 on revenue of $11.7B

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Related Articles

Sustainable investors face squeeze as larger firms move in

Return of short-selling bans: market protection or 'war against truth'?

How to make the most of a zero-commission world